Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 8:54 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 8:54 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
AMAG Pharmaceuticals Focuses on Product Development & Buyouts
by Zacks Equity Research
We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.
Pfizer's (PFE) Leukemia Candidate Receives Approval in EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises
by Arpita Dutt
Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.
Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy
by Zacks Equity Research
The pharma and biotech industry has been blessed with good health in the first half of the year.
Seattle Genetics (SGEN) Reports Positive Data for Adcetris
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion
by Zacks Equity Research
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
by Zacks Equity Research
Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.
Why You Should Add Novo Nordisk Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
by Zacks Equity Research
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Horizon Pharma Gets Health Canada Approval for Procysbi
by Zacks Equity Research
Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
by Arpita Dutt
The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.
Sanofi: Should Value Investors Consider SNY Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
by Zacks Equity Research
Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
by Zacks Equity Research
Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.
Intercept (ICPT) Releases Data from Phase II Flint Trial
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.
Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.
3 Large Cap Pharma Stocks to Buy Now
by Ryan McQueeney
Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.
Is the Options Market Predicting a Spike in Sanofi (SNY) Stock?
by Zacks Equity Research
Investors in Sanofi (SNY) need to pay close attention to the stock based on moves in the options market lately.